BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/29/2021 11:12:00 AM | Browse: 949 | Download: 1627
Publication Name World Journal of Gastroenterology
Manuscript ID 66039
Country Canada
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
Manuscript Source Invited Manuscript
All Author List Farah Albader, Petra Anna Golovics, Lorant Gonczi, Talat Bessissow, Waqqas Afif and Peter Laszlo Lakatos
ORCID
Author(s) ORCID Number
Farah Albader http://orcid.org/0000-0003-2657-4558
Petra Anna Golovics http://orcid.org/0000-0003-3195-183X
Lorant Gonczi http://orcid.org/0000-0002-8819-6460
Talat Bessissow http://orcid.org/0000-0003-2610-1910
Waqqas Afif http://orcid.org/0000-0001-6869-0982
Peter Laszlo Lakatos http://orcid.org/0000-0002-3948-6488
Funding Agency and Grant Number
Corresponding Author Peter Laszlo Lakatos, MD, PhD, Professor, Staff Physician, Division of Gastroenterology, McGill University, 1650 Cedar Avenue, Montreal H3G 1A4, Quebec, Canada. kislakpet99@gmail.com
Key Words Therapeutic drug monitoring; Inflammatory bowel disease; Biologic therapies; Loss of response; Reactive; Proactive
Core Tip In this review, we discuss the existing studies that looked at both proactive and reactive therapeutic drug monitoring (TDM) and concluded that in current practice, reactive TDM has been shown to be useful. When used as an adjunct to clinical assessment and biomarkers in patients with treatment failure, TDM has proven to be a valuable tool for subsequent management.
Publish Date 2021-09-29 11:12
Citation Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247
URL https://www.wjgnet.com/1007-9327/full/v27/i37/6231.htm
DOI https://dx.doi.org/10.3748/wjg.v27.i37.6231
Full Article (PDF) WJG-27-6231.pdf
Full Article (Word) WJG-27-6231.docx